A pair of Phase 3 reports spotlight ADC and maintenance approaches for relapsed or advanced small-cell lung cancer. In TAISHAN-302, Tam-Peli—an anti-B7-H3 antibody-drug conjugate—cut the risk of death by 54% versus topotecan in relapsed SCLC, addressing a second-line setting where response rates have historically been modest. In first-line maintenance, Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi more than halved the risk of death in certain small-cell lung cancer patients in a Phase 3 trial, according to an externally posted report of a 58% risk reduction versus Imfinzi alone. Together, the updates signal a continued shift toward more mechanism-driven SCLC regimens—using antibody-drug conjugates for relapsed disease and combining targeted immunotherapy components for ongoing tumor control.